Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of OH2 Oncolytic Virus in Advanced Solid Tumors
NCT05954091Phase 1Not yet recruiting
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
01
Overview
Phase 1, open-label, single-arm trial of OH2 in solid tumor, sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd. Primary endpoints: Incidence of Adverse Event (AE) and Serious Adverse Event (SAE) at 1 year and Maximum tolerated dose at 1 year. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
OH2
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05954091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954091.